ECOG EA3231 RAI-Refractory Thyroid Cancer with BRAF V600Em - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
EA3231, A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em (NCT06475989)
Principal Investigator
Head and Neck Oncologist
Protocol Number
IRB:
PRO00117489
NCT:
NCT06475989
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-681-4768